How can we help?
Whether you've been diagnosed or have concerns about prostate cancer, our Specialist Nurses are here to support you and answer your questions by phone, live chat or email. We also welcome contact from concerned partners, family members and friends as well as from health professionals.
How can we help?
Our Specialist Nurses offer up-to-date, reliable and balanced information on all aspects of prostate disease. In 2013, 9 out of 10 callers were very satisfied with their call and 82% agreed that the Specialist Nurses helped in a way other health professionals could not.
We also provide emotional support and can signpost callers to other organisations for additional help. Our nurses are however, unable to diagnose a medical condition and any information provided should not replace any medical advice given by your doctor.
We are a member of The Helplines Partnership and our service has been accredited to The Helplines Standard. This means that through independent assessment, we have demonstrated that we are committed to quality and offer a professional service.
We aim to answer over 85% of attempted calls to our nurses. However, there are times when the helpline can experience a high volume of calls and callers are given the option to queue. We know that there are more calls to the Specialist Nurses in the morning, so you are more likely to speak with a nurse on your first attempt if you call after 12 noon.
Many people have been calling about:
The news that the National Institute for Health and Care Excellence (NICE) has not approved the use of abiraterone prior to having chemotherapy on the NHS
Abiraterone can be accessed prior to chemotherapy through the Cancer Drugs Fund (CDF). At present the decision by NICE affects men who have not yet had chemotherapy and were wanting to access abiraterone on the NHS. Men who are already taking abiraterone will continue to be able to access this medicine through the CDF.
Please contact one of our Specialist Nurses on 0800 074 8383 to find out more about NICE’s decision, access to abiraterone and the CDF.